Possible Effective Treatment Alternative for Blood Cancer at EHA
Potential to Address Both Solid and Blood Cancers if Clinical Trials Succeed in the Future
[Financial News] Sillajen announced on the 17th that its anticancer drug ‘BAL0891’, currently under development, received attention for presenting two clinical and preclinical studies at the European Hematology Association (EHA 2025), one of the most prestigious conferences in the field of blood cancer. EHA 2025, held from June 12 to 15 in Milan, Italy, is a global conference representing the field of blood cancer alongside the American Society of Hematology (ASH). This marks the first time Sillajen’s pipeline has been presented at such an international conference.
Sillajen is expanding BAL0891, initially being developed for solid tumors, into the area of blood cancers, including acute myeloid leukemia (AML). Through this EHA presentation, the company demonstrated significant potential in both clinical trial plans and preclinical results, showcasing their technological capabilities on a global stage.
The first presentation focused on a Phase 1 clinical trial for patients with relapsed or refractory AML, which is planned to proceed under the approval of the U.S. Food and Drug Administration (FDA). This clinical trial will evaluate safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). It will include pharmacokinetic (PK) and pharmacodynamic (PD) analyses, assessment of AML treatment response, minimal residual disease (MRD) analysis, and RNA sequencing-based gene expression signature analysis.
The second presentation was a preclinical study of BAL0891 conducted by Professor Cho Byung-sik’s team at Seoul St. Mary’s Hospital, The Catholic University of Korea. The study introduced experimental results in AML cell lines and animal models.
According to the research, BAL0891 showed strong anticancer effects when used alone, and the effect was further enhanced when combined with venetoclax or azacitidine. In animal models, BAL0891 demonstrated an extension in survival time and tumor growth suppression, receiving positive feedback for not presenting side effects such as weight loss concerning safety.
A Sillajen representative stated, “This conference presentation shows the possibility that BAL0891 could be an effective treatment alternative for blood cancers.” They added, “If meaningful results are derived from future clinical trials, we aim to develop it into a platform pipeline covering both solid and blood cancers.”